CRECON MEDICAL ASSESSMENT

JP

Publications

Publications

Presentation

  • Yuzuriha T, Den R, Yumoto Y, Aoshima KInoue S, Chikashima H. Burden of illness for alcohol dependence using health insurance claims database in Japan. Nihon Arukoru Yakubutsu Igakkai 2019, Poster. October 4-6, 2019, Sapporo, Japan (in Japanese).

  • Liu G, Kobayashi M, Pizzi L T. Drug Pricing and Value Perspectives on the US versus Asia. ISPOR 2019, New Orleans, LA, USA. ISPOR Forum. May 20, 2019.

  • Kusumi I, Inoue S, Baba K, Nosaka T, Anzai T. Inspection of the cardiovascular event onset risk by therapeutic drug for Schizophrenia:Cohort study using medical information database. The 115th Annual Meeting of the Japanese Society of Psychiatry and Neurology. June 20-22, 2018, Niigata, Japan. (in Japanese)

  • Murata T, Suzukamo Y, Shiroiwa T, Taira N, Shimozuma K. RESPONSE SHIFT EFFECT ON QUALITY OF LIFE IN RANDOMIZED CONTROL TRIAL OF TAXANE VERSUS S-1 FOR METASTATIC BREAST CANCER PATIENTS (SELECT-BC): STRUCTURAL QUATION MODELING. ISPOR Europe, Barcelona, Spain. Poster Presentation. Nov 14, 2018.

  • Kaku K, Haneda M, Sakamaki H, Yasui A, Murata T, Ustyugova AV, Chin R, Hirase T, Shibahara T, Hayashi N, Kansal A, Kaspers S, Okamura T. COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN JAPAN BASED ON RESULTS FROM THE SUBGROUP ANALYSIS OF ASIAN PATIENTS IN THE EMPA-REG OUTCOME TRIAL. ISPOR Europe, Barcelona, Spain. Poster Presentation. Nov 13, 2018.

Series

  • Kobayashi M.Value-based Approach [38] Learning the SIR Model with Novel Coronavirus- Introduction to analysis guideline(14) Modeling⑨System dynamics. Monthly Medical Information Express. 2021; 3:72-74. (in Japanese)

  • Kobayashi M.Value-based Approach [37] Introduction to analysis guideline(13) Modeling⑧Limitations and countermeasures of Markov models. Monthly Medical Information Express. 2021; 2:78-80. (in Japanese)

  • Kobayashi M.Value-based Approach [36] Introduction to analysis guideline(12) Modeling⑦Outcome calculation by Markov model We challenge a change method of the long-term medical cost and outcome. Monthly Medical Information Express. 2021; 1:78-80. (in Japanese)

  • Kobayashi M.Value-based Approach [35] Introduction to analysis guideline(11) Modeling⑥Cohort simulation utilizing the Markov model Let’s simulate long-term change of the chronic disease. Monthly Medical Information Express. 2020; 12:72-74. (in Japanese)

  • Kobayashi M.Value-based Approach [34] Introduction to analysis guideline(10) Modeling⑤Structure of the Markov model Learn the optimal Markov model for an analysis of the chronic disease. Monthly Medical Information Express. 2020; 11:80-82. (in Japanese)

Books

  • Inoue S. Chapter 9. Cost-effectiveness analysis of drugs and  application to market access. Section 2. Cost-effectiveness analysis of drugs and utilization of drug price application. Technical Information Institute co,. LTD. 2019. (in Japanese)

  • Inoue S. Chapter 6. Health care, economic and value of self-injection, dropping to the doctors and the patient needs and product development for the valuation of self-injection. Self-injection to think from Section 2 medical economic point of view medical fee points. (Regulatory Science).2016. (in Japanese)

  • Kobayashi M. Model analysis in the medical economic evaluation. Basic medical economic evaluation -to understand cost-effectiveness definitely- (Regulatory Science).2015, Page.103-125.(in Japanese)

  • Kobayashi M. Specific method of utilizing Pharmacoeconomics. Technical Information Institute co,. LTD. (Nagase T et al eds). 2014. (in Japanese).2014.

  • Inoue S. Development strategy on the basis of the real condition and clinical condition, a mechanism of the treatment of sepsis. Technical Information Institute co,. LTD. (Hayakawa M et al eds). 2013. (in Japanese)

TOP
費用対効果分析

Cost-effectiveness analysis

To evaluate the cost-effectiveness of pharmaceuticals and medical devices by pharmacoeconomics (medical economic assessment), many specialized technologies and knowledge should be combined. We evaluate the cost-effectiveness of medical technologies using advanced modeling and statistical analysis technologies that we have developed over many years.

  • Cost-effectiveness analysis
  • Decision-making model construction
  • Review of previous studies
  • Systematic review
  • Indirect comparison/
    network meta-analysis
  • Budget impact analysis
    in the introduction of new pharmaceuticals
疾病負担分析

Burden of illness analysis

The socio-economic burden of disease is correlated with the therapeutic value of the disease. However, the estimation of such disease burdens is hardly done. We conduct burden of illness analysis to estimate epidemiological parameters, including the numbers of patients and events, long-term survival rates, and medical expenses.

  • Quantification of a target disease’s
    financial burden
  • Estimation and prediction of the number of patients
  • Estimation of lifetime medical expenses
  • Estimation of expected survival time
リアルワールドデータ

Real-world data/
Patient outcome data analyses

Real-world data, such as medical and receipt data, and patient outcome data are analyzed based on advanced statistical knowledge and technology.

  • Planning of survey/
    Development of protocols
  • Medical data analysis
  • Claims data analysis
  • QOL survey
  • Conjoint analysis/
    Discrete choice experiment (DCE)
  • Exploratory analysis
教育及び各種コンサルティング

Education
and other consulting services

We support in-house educational and enlightenment activities related to pharmacoeconomics (medical economic assessment) and health technology assessment (HTA), and provide consulting services. Furthermore, we provide consulting services based on review and summarization of technology appraisal (TA) by the UK’s National Institute for Health and Clinical Excellence (NICE).

  • Lecture/Workshop
  • Other consulting services
  • Review of NICE TA